Fig. 2.

YIAD001 and YIAD002 ameliorates the expression levels of AD-related biomarkers. YIAD001 (50 mg/kg/day, n = 6) and YIAD002 (50 mg/kg/day, n = 6) were orally administered to 4.5-month-old female 5XFAD mice for 5 weeks. Through western blot, soluble fractions of cortical lysates were immunoblotted for AT8 and tau (A), Iba1 and GFAP (B), PSD95 and synaptophysin (C), and actin (A–C). Relative intensities of the blots were quantified in ratio to actin and statistically compared to vehicle-treated 5XFAD mice (Vehicle). Full blot images are provided in additional files. One-way analysis of variance followed by Bonferroni’s post hoc comparisons tests were performed in all statistical analyses (*P<0.05, **P<0.01, ***P<0,001, ****P<0.0001). Data are presented as mean ± SEM